LDS/Medical Tests/CALU Gene Mutation Analysis

CALU Gene Mutation Analysis

Calumenin, encoded by the CALU gene, is a molecular chaperone that inhibits transfer of reduced vitamin K from VKORC1, the pharmacological target of warfarin, to the γ-carboxylase. Because of its polymorphic structure and central role in the warfarin metabolic pathway, a contributory role for calumenin to warfarin dose variability has been posited.

There are four known SNPs in the coding region: rs1043550 (3’UTR), rs11653 (3’UTR), rs339097 (intronic), and rs2290228 (11G>A, Arg4Gln). Of these, only rs339097 has been shown to have an effect on warfarin dosage requirements.

  • Warfarin therapy selection and optimization
  • Predict/optimize warfarin dosage requirements
  • rs339097 AA – homozygous wild-type - may require a lower maintenance dose of warfarin compared to patients with GA or GG genotype
  • rs339097 AG – heterozygous - may require a higher maintenance dose compared to patients with the AA genotype
  • rs339097 GG – homozygous variant – may require a higher dose compared to patients with the AA genotype

Note: Other genetic and clinical factors may also influence warfarin dose.

rs339097 AA – homozygous wild-type - may require a lower maintenance dose of warfarin compared to patients with GA or GG genotype

Polymerase Chain Reaction (PCR)/Allele Specific Primer Extension (ASPE), Sequencing.

Buccal swabs or Whole blood. 

ACD yellow top tube is preferred, EDTA lavender top tube also accepted.

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
VKORC1 genotyping should also be considered in warfarin dosing.
4-14 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login